All news

Exagen Q3 revenue rises 7% to

GlobeNewswire · · AI-summarised by FinFlash

Diagnostics company Exagen reported third-quarter revenue of

So What?

Steady growth and unchanged guidance offer limited surprise for XGN; cash levels and the planned early-2027 myositis test launch are the items to watch.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.